Patent Search

Invention Title	METHOD FOR THE FORMATION OF NON-INVASIVE INTRANASAL NANOPARTICLES FUNCTIONALIZED WITH ANTI-EPHA3
Publication Number	16/2021
Publication Date	16/04/2021
Publication Type	INA
Application Number	202111016861
Application Filing Date	10/04/2021
Priority Number	
Priority Country	
Priority Date	
Field Of Invention	BIOTECHNOLOGY
Classification (IPC)	B09C0001000000, A61K0009000000, C08G0018320000, C09D0193000000, C08G0018080000

Inventor

Name	Address	Country	Nat
Dr. SANDEEP KUMAR SHUKLA	School of Pharmacy, Sharda University, Plot No. 32, 34, Knowledge Park III, Greater Noida, Uttar Pradesh 201310, India	India	Indi
Dr. SHOBHIT SRIVASTAVA	School of Pharmacy, Sharda University, Plot No. 32, 34, Knowledge Park III, Greater Noida, Uttar Pradesh 201310, India	India	Indi
Dr. GUNJAN	School of Pharmacy, Sharda University, Plot No. 32, 34, Knowledge Park III, Greater Noida, Uttar Pradesh 201310, India	India	Indi
Dr. AMIT K. KESARI	Assistant professor, Faculty of Pharmacy, Dehradun Institute of Technology University (DITU), Mussoorie Diversion Road, Makka Wala, Dehradun, Uttarakhand - 248009, India, India	India	Indi
Dr. SAURABH SRIVASTAVA	Era College of Pharmacy, Era University, Lucknow, Uttar Pradesh 226003, India	India	Indi
Dr. NISHA SHARMA	Assistant professor, Faculty of Pharmacy, Dehradun Institute of Technology University (DITU), Mussoorie Diversion Road, Makka Wala, Dehradun, Uttarakhand - 248009, India	India	Indi
Dr. PRAFULLA CHANDRA TIWARI	Department of Pharmacology, King George's Medical University, Lucknow, Uttar Pradesh 226003	India	Indi
SUNNY	School of Medical and Allied Science, Galgotias University, Greater Noida, Uttar Pradesh 203201	India	Indi
ARTI GUPTA	School of Pharmacy, Sharda University, Plot No. 32, 34, Knowledge Park III, Greater Noida, Uttar Pradesh 201310	India	Indi

Applicant

Name	Address	Country	Nat
SHARDA UNIVERSITY	School of Pharmacy, Sharda University, Plot No. 32, 34, Knowledge Park III, Greater Noida, Uttar Pradesh 201310, India	India	Indi
Dr. SANDEEP KUMAR SHUKLA	School of Pharmacy, Sharda University, Plot No. 32, 34, Knowledge Park III, Greater Noida, Uttar Pradesh 201310, India	India	Indi
Dr. SHOBHIT SRIVASTAVA	School of Pharmacy, Sharda University, Plot No. 32, 34, Knowledge Park III, Greater Noida, Uttar Pradesh 201310, India	India	Indi
Dr. GUNJAN	School of Pharmacy, Sharda University, Plot No. 32, 34, Knowledge Park III, Greater Noida, Uttar Pradesh 201310, India	India	Indi
Dr. AMIT K. KESARI	Assistant professor, Faculty of Pharmacy, Dehradun Institute of Technology University (DITU), Mussoorie Diversion Road, Makka Wala, Dehradun, Uttarakhand - 248009, India, India	India	Indi
Dr. SAURABH SRIVASTAVA	Era College of Pharmacy, Era University, Lucknow, Uttar Pradesh 226003, India	India	Indi
Dr. NISHA SHARMA	Assistant professor, Faculty of Pharmacy, Dehradun Institute of Technology University (DITU), Mussoorie Diversion Road, Makka Wala, Dehradun, Uttarakhand - 248009, India	India	Indi
Dr. PRAFULLA CHANDRA TIWARI	Department of Pharmacology, King George's Medical University, Lucknow, Uttar Pradesh 226003	India	Indi
SUNNY	School of Medical and Allied Science, Galgotias University, Greater Noida, Uttar Pradesh 203201	India	Indi
ARTI GUPTA	School of Pharmacy, Sharda University, Plot No. 32, 34, Knowledge Park III, Greater Noida, Uttar Pradesh 201310	India	Indi

Abstract:

A method for the formation of non-invasive intranasal nanoparticles functionalized with anti-EPHA3, the method (100) comprising steps of: dissolving Cink4t and Poly (D, L Lactide-co-glycolide) in dimethyl sulfoxide (DMSO) to form a non-aqueous phase liquid; adding prepared non-aqueous phase liquid to 1% weight by volume (w/v) poloxam in deionized water; stirring the mixture for a period of 3 hours to remove organic solvent; centrifuging the mixture to separate nanoparticles; and washing the nanoparticl deionized water to remove free Cink4t.

Complete Specification

Embodiments of the present invention generally relate to a method of developing dual-targeted Cink4T-Anti-EPHA3 functionalized intranasal nanoparticles and particularly to the method of developing dual-targeted Cink4T-Anti-EPHA3 functionalized intranasal nanoparticles for the management of high-grade Glioblastoma.

[003] DESCRIPTION OF RELATED ART

[004] Intracranial malignancies represent 1.4% in all diagnosed cancers and Glioblastoma (GBM) is one of the most aggressive malignant tumors with overall dismal survival averaging one year despite multimodality therapeutic interventions including surgery, radiotherapy, and concomitant and adjuvant chemotherapy. GBM is the most common primary brain tumor and lethal as well in adults. Globally it counts the 3.5 cases per 100000 people every year. The cancerous tissues invade the surrounding cells making it impossible to cure surgically. Moreover, GBM is amongst the most resistant to chemotherapy and radiation

View Application Status